Outlook Wealth Advisors LLC Makes New $433,000 Investment in Medpace Holdings, Inc. (NASDAQ:MEDP)

Outlook Wealth Advisors LLC bought a new stake in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 1,302 shares of the company’s stock, valued at approximately $433,000.

Several other large investors also recently modified their holdings of MEDP. Stone House Investment Management LLC purchased a new stake in shares of Medpace during the 3rd quarter valued at approximately $33,000. Ashton Thomas Securities LLC bought a new stake in Medpace during the 3rd quarter valued at $37,000. Capital Performance Advisors LLP bought a new position in shares of Medpace in the third quarter worth $46,000. True Wealth Design LLC grew its position in shares of Medpace by 16,800.0% in the third quarter. True Wealth Design LLC now owns 169 shares of the company’s stock valued at $56,000 after purchasing an additional 168 shares in the last quarter. Finally, Northwestern Mutual Wealth Management Co. raised its stake in shares of Medpace by 95.7% during the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 225 shares of the company’s stock valued at $93,000 after purchasing an additional 110 shares during the period. Hedge funds and other institutional investors own 77.98% of the company’s stock.

Medpace Trading Up 1.3 %

Shares of NASDAQ:MEDP opened at $335.23 on Thursday. The company has a 50-day moving average price of $341.36 and a 200-day moving average price of $358.26. The company has a market cap of $10.42 billion, a price-to-earnings ratio of 29.35, a price-to-earnings-growth ratio of 1.80 and a beta of 1.36. Medpace Holdings, Inc. has a 12 month low of $277.72 and a 12 month high of $459.77.

Medpace (NASDAQ:MEDP) last released its quarterly earnings results on Monday, October 21st. The company reported $3.01 EPS for the quarter, beating analysts’ consensus estimates of $2.77 by $0.24. Medpace had a return on equity of 50.87% and a net margin of 17.66%. The business had revenue of $533.32 million during the quarter, compared to analyst estimates of $540.99 million. During the same quarter in the prior year, the company posted $2.22 EPS. Medpace’s quarterly revenue was up 8.3% compared to the same quarter last year. As a group, research analysts forecast that Medpace Holdings, Inc. will post 11.93 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities analysts have commented on MEDP shares. William Blair reissued an “outperform” rating on shares of Medpace in a research note on Tuesday, October 22nd. Jefferies Financial Group downgraded shares of Medpace from a “buy” rating to a “hold” rating and dropped their price objective for the stock from $415.00 to $345.00 in a report on Wednesday, September 25th. Redburn Atlantic started coverage on Medpace in a research note on Monday, October 14th. They issued a “buy” rating and a $404.00 target price on the stock. UBS Group lowered Medpace from a “buy” rating to a “neutral” rating and dropped their price target for the stock from $420.00 to $350.00 in a research note on Friday, September 27th. Finally, Robert W. Baird increased their price objective on Medpace from $349.00 to $354.00 and gave the company a “neutral” rating in a research report on Monday, November 25th. Seven analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $380.56.

About Medpace

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.